These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 37257732)

  • 1. A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety.
    Thakur A; Chorawala MR; Patel RS
    Crit Rev Oncol Hematol; 2023 Aug; 188():104034. PubMed ID: 37257732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
    Pastorino A; Di Bartolomeo M; Maiello E; Iaffaioli V; Ciuffreda L; Fasola G; Di Costanzo F; Frassineti GL; Marchetti P; Antoniotti C; Leone F; Zaniboni A; Aprile G; Zilocchi C; Sobrero A; Bordonaro R
    Clin Colorectal Cancer; 2018 Sep; 17(3):e457-e470. PubMed ID: 29605592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
    Jo H; Lee MS; Lee YP; Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST
    Clin Oncol (R Coll Radiol); 2022 Aug; 34(8):e323-e328. PubMed ID: 35248464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
    Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
    Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA-Compliant single-arm Meta-Analysis of noncomparative clinical studies and randomized controlled trials.
    Ge P; Reyila A; Li XY; Liu SY; Jiang YX; Yang YJ; Li XL; Bian Y
    J Clin Pharm Ther; 2022 Jun; 47(6):798-808. PubMed ID: 35229901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aflibercept.
    Ciombor KK; Berlin J; Chan E
    Clin Cancer Res; 2013 Apr; 19(8):1920-5. PubMed ID: 23444216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
    Ruff P; Van Cutsem E; Lakomy R; Prausova J; van Hazel GA; Moiseyenko VM; Soussan-Lazard K; Dochy E; Magherini E; Macarulla T; Papamichael D
    J Geriatr Oncol; 2018 Jan; 9(1):32-39. PubMed ID: 28807738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study.
    Piringer G; Thaler J; Anchisi S; Geffriaud-Ricouard C; Gueldner M; Scholten F; Derigs HG; Bohanes P; Grünberger B; Schwarz L; von Moos R; Hofheinz RD
    J Geriatr Oncol; 2023 Nov; 14(8):101638. PubMed ID: 37776611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer.
    Lau DK; Mencel J; Chau I
    Expert Opin Drug Saf; 2022 May; 21(5):589-597. PubMed ID: 34986714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
    Ruff P; Ferry DR; Lakomỳ R; Prausová J; Van Hazel GA; Hoff PM; Cunningham D; Arnold D; Schmoll HJ; Moiseyenko VM; McKendrick JJ; Ten Tije AJ; Vishwanath RL; Bhargava P; Chevalier S; Macarulla T; Van Cutsem E
    Eur J Cancer; 2015 Jan; 51(1):18-26. PubMed ID: 25466509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
    Lapeyre-Prost A; Pernot S; Sigrand J; Le Malicot K; Mary F; Aparicio T; Dahan L; Caroli-Bosc FX; Lecomte T; Doat S; Marthey L; Desrame J; Lepage C; Taieb J
    Clin Colorectal Cancer; 2020 Dec; 19(4):285-290. PubMed ID: 32921581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
    Riechelmann RP; Srimuninnimit V; Bordonaro R; Kavan P; Di Bartolomeo M; Maiello E; Cicin I; García-Alfonso P; Chau I; Fedyanin MY; Martos CF; Ter-Ovanesov M; Peeters M; Ko YJ; Yalcin S; Karthaus M; Aparicio J; Heinemann V; Picard P; Bury D; Drea E; Sobrero A
    Clin Colorectal Cancer; 2019 Sep; 18(3):183-191.e3. PubMed ID: 31221542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen.
    Martínez-Lago N; Cameselle García S; Alonso de Castro B; Gómez-Randulfe Rodríguez MI; Carmona Campos M; González Villarroel P; Salgado Fernández M; De la Cámara Gómez JC; Romero Reinoso C; Cousillas Castiñeiras A; Méndez Méndez JC; Vidal Insua Y; Fernández-Montes A
    PLoS One; 2022; 17(6):e0269399. PubMed ID: 35657983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
    Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A
    Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
    Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ
    Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
    Chong DQ; Manalo M; Imperial M; Teo P; Yong G; Ng M; Tan IB; Choo SP; Chua C
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):275-83. PubMed ID: 27075236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept: A Review in Metastatic Colorectal Cancer.
    Syed YY; McKeage K
    Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
    Salgado Fernández M; Pérez Hoyos MT; Díaz de Corcuera I; Vidal Arbués A; García de la Torre M
    Expert Opin Drug Saf; 2015 Aug; 14(8):1171-9. PubMed ID: 26076885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.
    Chau I; Joulain F; Iqbal SU; Bridgewater J
    BMC Cancer; 2014 Aug; 14():605. PubMed ID: 25142418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
    J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.